If you can't stop the beta-amyloid protein plaques from forming in Alzheimer's disease patients, then maybe you can help the body rid itself of them instead. At least that's what scientists from New York were hoping for when they found a drug candidate to do just that. Their work appears in a research report online on March 2, 2011, in The FASEB Journal, and shows that a new compound, called "SMER28" stimulated autophagy in rat and mice cells. Autophagy is a process cells use to "clean out" the debris from their interior, including unwanted materials such as the protein aggregates that are hallmarks of Alzheimer's disease. In mice and rat cells, SMER28 effectively slowed down the accumulation of beta-amyloid. "Our work demonstrates that small molecules can be developed as therapies, by activating a cellular function called autophagy, to prevent Alzheimer's disease," said senior author Dr. Paul Greengard, Nobel laureate and director of the Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University in New York, NY. "By increasing our understanding of autophagy, it might be possible to stimulate it pharmacologically or naturally to improve the quality of life for aging people." Using mouse and rat cells, scientists tested various compounds for their ability to reduce the buildup of beta-amyloid by exposing cultured cells to compounds known to activate autophagy. The effects of these compounds were then compared by removing growth factors from the culture medium. Researchers then focused on the most effective compound, which was SMER28, to characterize the cellular components involved in this phenomenon. For that purpose, the effect of SMER28 on beta-amyloid formation was compared using normal cells or cells where the expression of genes known to be involved in autophagy was reduced or abolished.
Login Or Register To Read Full Story